<u>Materials Design Analysis Reporting (MDAR)</u> Checklist for Authors

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: doi:10.31222/osf.io/9sm4x.). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

Materials

Antibodies	Yes (indicate where provided: section/paragraph)	n/a
For commercial reagents, provide supplier name, catalogue number and RRID, if available.	Yes(RNA extraction, library preparation, RNA-seq Quantitative real-time PCR validation qRT/PCR /pa ragraph8、9、13)	

Cell materials	Yes (indicate where provided: section/paragraph)	n/a
Cell lines: Provide species information, strain. Provide accession number in repository OR supplier name, catalog number, clone number, OR RRID	Yes(Cell culture/paragraph 10)	
Primary cultures: Provide species, strain, sex of origin, genetic modification status.		n/a Primary culture was not involved in this st udy

Experimental animals	Yes (indicate where provided: section/paragraph)	n/a
Laboratory animals: Provide species, strain, sex, age,		n/a
genetic modification status. Provide accession		No anim
number in repository OR supplier name, catalog		al experi
number, clone number, OR RRID		ments w
		ere invol
		ved in th
		is study
Animal observed in or captured from the		n/a
field: Provide species, sex and age where		No anim
possible		al experi
		ments w
		ere invol
		ved in th
		is study
Model organisms: Provide Accession number		n/a
in repository (where relevant) OR RRID		No anim
		al experi
		ments w
		ere invol
		ved in th
		is study

Plants and microbes	Yes (indicate where provided: section/paragraph)	n/a
Plants: provide species and strain, unique accession		n/a
number if available, and source (including location		No plant
for collected wild specimens)		s were i
		nvolved
		in this st
		udy
Microbes: provide species and strain, unique		n/a
accession number if available, and source		No micr
		oorganis
		ms were
		involve
		d in this
		study

DRAFT | June 2019

Human research participants	Yes (indicate where provided: section/paragraph)	n/a
Identify authority granting ethics approval (IRB or	Yes(Footnote/paragraph 35)	
equivalent committee(s), provide reference number		
for approval.		
Provide statement confirming informed consent	Yes(Study samples/paragraph 7)	
obtained from study participants.		
Report on age and sex for all study participants.	Yes(Study samples/paragraph 7)	

De

Study protocol	Yes (indicate where provided: section/paragraph)	n/a
For clinical trials, provide the trial registration		n/a
number OR cite DOI in manuscript.		This stud
		y has pas
		sed the 0
		hinese et
		hical rev
		ew and
		meets th
		e require
		ments o
		clinical
		rials
Laboratory protocol	Yes (indicate where provided: section/paragraph)	n/a
Provide DOI or other citation details if detailed step-		n/a
by-step protocols are available.		Not prov
		ided in th
		is study
Experimental study design (statistics details)	Yes (indicate where provided: section/paragraph)	n/a
State whether and how the following have been	Yes(Study samples/paragraph 7)	II/ a
done, or if they were not carried out.	. co(ctat) campies, paragraph, ,	
Sample size determination	Yes(Study samples/paragraph 7)	
Randomisation	Yes(Study samples/paragraph 7)	
	·(,,, p,	1
		n/a
Blinding		n/a Blinding

State whether and how the following have been	Yes(Study samples/paragraph 7)	
done, or if they were not carried out.		
Sample size determination	Yes(Study samples/paragraph 7)	
Randomisation	Yes(Study samples/paragraph 7)	
Blinding		n/a
		Blinding
		was not i
		nvolved i
		n this stu
		dy
Inclusion/exclusion criteria	Yes(Study samples/paragraph 7)	

Sample definition and in-laboratory replication	Yes (indicate where provided: section/paragraph)	n/a
State number of times the experiment was		n/a
replicated in laboratory		The resul
		ts of clini
		cal tests,
		cell tests
		and qPC
		R tests w
		ere consi
		stent, No
		repeat t
		est yet
Define whether data describe technical or biological replicates	Yes(qRT/PCR /paragraph13)	

Ethics	Yes (indicate where provided: section/paragraph)	n/a
--------	--	-----

Studies involving human participants: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	Yes(Footnote/paragraph 35)	
Studies involving experimental animals: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.		n/a No anim al experi ments w ere invol ved in thi s study
Studies involving specimen and field samples: State if relevant permits obtained, provide details of authority approving study; if none were required, explain why.		n/a No speci men and field sa mples w ere invol ved in thi s study

Dual Use Research of Concern (DURC)	Yes (indicate where provided: section/paragraph)	n/a
If study is subject to dual use research of concern,		n/a
state the authority granting approval and reference		This stud
number for the regulatory approval		y has no
		dual pur
		pose

<u>Analysis</u>

Attrition	Yes (indicate where provided: section/paragraph)	n/a
State if sample or data point from the analysis is		n/a
excluded, and whether the criteria for exclusion were		All sample
determined and specified in advance.		s meet the
		inclusion
		criteria

Statistics	Yes (indicate where provided: section/paragraph)	n/a
Describe statistical tests used and justify choice of	Yes(Statistical analysis/paragraph 14)	
tests.		

Data Availability	Yes (indicate where provided: section/paragraph)	n/a
State whether newly created datasets are available,		n/a
including protocols for access or restriction on		The main
access.		data of thi
		s study ha
		ve been in
		cluded in t
		he original
		text
If data are publicly available, provide accession		n/a
number in repository or DOI or URL.		The main
		data of thi
		s study ha
		ve been in
		cluded in t
		he original
		text
If publicly available data are reused, provide		n/a
accession number in repository or DOI or URL, where		The main
possible.		data of thi
		s study ha
		ve been in
		cluded in t
		he original
		text

Code Availability	Yes (indicate where provided: section/paragraph)	n/a
For all newly generated code and software essential		n/a
for replicating the main findings of the study:		This study
		does not
		involve
State whether the code or software is available.		n/a
		This study
		does not
		involve
If code is publicly available, provide accession		n/a
number in repository, or DOI or URL.		This study
		does not
		involve

Reporting

Adherence to community standards	Yes (indicate where provided: section/paragraph)	n/a
MDAR framework recommends adoption of		
discipline-specific guidelines, established and		
endorsed through community initiatives. Journals		

DRAFT | June 2019

have their own policy about requiring specific guidelines and recommendations to complement MDAR.		
State if relevant guidelines (eg., ICMJE, MIBBI,	ICMJE guidelines were followed, as the journal follows	
ARRIVE) have been followed, and whether a checklist	ICMJE recommendations for publication.	
(eg., CONSORT, PRISMA, ARRIVE) is provided with		
the manuscript.		

Article information: https://dx.doi.org/10.21037/atm-21-5176	